Last reviewed · How we verify
Cardiovascular disease
Approved treatments
- Colcrys · Scilex Pharms
Colcrys works by inhibiting the activity of a specific enzyme called serine/threonine-protein kinase pim-1. - Repatha · Repatha
Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cardiovascular disease patent landscape — cliff calendar, originator estates, attackable patents
- Cardiovascular disease treatment landscape brief
- Cardiovascular disease treatment updates RSS
Frequently asked questions about Cardiovascular disease
What drugs treat Cardiovascular disease?
Tracked treatments include Colcrys, Repatha.
What is the treatment for Cardiovascular disease?
Standard treatment for Cardiovascular disease includes Colcrys, Repatha. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cardiovascular disease patent cliff · Cardiovascular disease CI report
- Treatment: Colcrys · Scilex Pharms
- Treatment: Repatha · Repatha
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing